CARDIFF, CA--(Marketwire - July 7, 2008) - NeuroInvestment today announced the release of its July/August issue, which overviews the CNS sector at midyear, and previews the second half of 2008. The major news at midyear was the Alzheimer's data which came from high-profile programs at Elan/Wyeth and at Myriad Genetics. The issue takes a hard look at those results, and notes the relationship of the Flurizan failure to an increasingly virulent tendency to shortchange Phase II studies. Other commentaries look at Merck's migraine data, Vanda Pharmaceuticals' tasimelteon data and their claims of personalized medicine; and the problems at Jazz Pharmaceuticals. Capsule reviews for 67 neuro-focused companies are included, and an overview of Avigen.

The second half of 2008 will feature clinical data from a variety of companies. Important Phase II data is expected from Allon Therapeutics (TSX: NPC) (post-CABG MCI and schizophrenia), Acadia Pharmaceuticals (Parkinson's psychosis), Avigen (MS spasticity), Catalyst Pharmaceuticals (cocaine addiction), Ceregene (Parkinson's), Cortex Pharmaceuticals (AMEX: COR) respiratory depression), EnVivo Pharmaceuticals (schizophrenia and Alzheimer's), Evotec (smoking cessation), Medivation (Huntington's), Neuren (post-CABG MCI), Neurogen (insomnia), Targacept (NASDAQ: TRGT) with AstraZeneca (schizophrenia and Alzheimer's), TorreyPines (Sjogren's), Trophos (neuropathic pain). And many eyes will be tracking the fate of iloperidone/Fanapta's NDA, important to both Vanda Pharmaceuticals and Titan, as well as Zogenix's efforts to find a window for its IPO, for which the climate could hardly be worse.

Recent issues of NeuroInvestment have included our June review of the Multiple Sclerosis area, featuring information on advanced programs from BioMS, Biogen-Idec, Active Biotech, and Novartis. The next issue of NeuroInvestment will be our annual review of the Alzheimer's area, incorporating what has been learned from the full and partial failures of recent weeks and assessing the implications for the rest of the field.

NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year corporate subscription is $1600, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three month trial subscription is US$600. Individual investor information is available upon request.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and CNS Disorders/Therapeutics since 2007. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.